Erastin analog with greatly improved system xc- (SLC7A11/xCT + SLC3A2/4F2hc) inhibitory potency and ferropotosis induction efficacy
Erastin2 is an Erastin analog with greatly improved system xc- (SLC7A11/xCT + SLC3A2/4F2hc) inhibitory potency (Erastin2 IC50 = 3.5 nM/CCF-STTG1; Erastin IC50 = 200 nM/HT-1080, 140 nM/Calu-1; Glu release assay) and ferropotosis induction efficacy (HT-1080 EC50 = 150 nM/Erastin2 vs. 1.2 μM/Erastin).
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
Journal of the American Chemical Society, 138(43), 14338-14346 (2016-11-03)
Iron is essential for sustaining life, as its ability to cycle between multiple oxidation states is critical for catalyzing chemical transformations in biological systems. However, without proper regulation, this same redox capacity can trigger oxidative stress events that contribute to
How cancer cells respond to nutrient deprivation remains poorly understood. In certain cancer cells, deprivation of cystine induces a non-apoptotic, iron-dependent form of cell death termed ferroptosis. Recent evidence suggests that ferroptosis sensitivity may be modulated by the stress-responsive transcription
Biochemistry and biophysics reports, 9, 266-272 (2017-09-29)
The inflammatory response in the central nervous system involves activated microglia. Under normal conditions they remove damaged neurons by phagocytosis. On the other hand, neurodegenerative diseases are thought to involve chronic microglia activation resulting in release of excess glutamate, proinflammatory
Biochemical and biophysical research communications, 497(1), 233-240 (2018-02-11)
Heart failure (HF) is the end stage of cardiovascular disease and is characterized by the loss of myocytes caused by cell death. Puerarin has been found to improve HF clinically, and animal study findings have confirmed its anti-cell-death properties. However
Exchange of extracellular cystine for intracellular glutamate by the antiporter system xc (-) is implicated in numerous pathologies. Pharmacological agents that inhibit system xc (-) activity with high potency have long been sought, but have remained elusive. In this study
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
